Skip to content

Author

A. Maniam

We have 5 of 49 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Non-Conventional Histologies of Prostate Cancer: From Morphology to Biology-Driven Precision Oncology.

Non-conventional prostate cancer histologies represent a small but clinically significant subset characterised by aggressive behaviour, atypical biomarker profiles, and reduced dependence on androgen receptor signalling. Evidence indicates these histologies reflect dynamic biological states driven by genomic instabilit...

F. Flauto, G. Neola, Alessia Cimadamore et al. · 0 citations
Open access Aug 2026

IUC26667-92 Assessment of QRISK®3 and Major Cardiovascular Events in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with ADT ± ARPI ± Docetaxel: A Retrospective Cohort Study

Abstract Background Cardiovascular disease is a major source of morbidity in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen deprivation therapy (ADT)-based treatment. Although cardiovascular risk assessment is increasingly recommended before treatment initiation, its integration i...

T. Alom, A. Kutty, G. Neola et al. · 0 citations
Open access Aug 2026

IUC26692-90 Benchmarking Artificial Intelligence-Based Clinical Prediction Models for Immune Checkpoint Inhibitor Response and Overall Survival in Bladder Cancer

AI models show moderate-to-good discrimination for ICI response and OS prognosis in BLCA, but evidence is constrained by reliance on a single trial cohort (IMvigor210) and training cohort (TCGA-BLCA), with internal and external OS validation each corroborated by only one study, limiting generalisability.

R. Das, B. Gonsalves, V. Ravindran et al. · 0 citations
Open access Aug 2026

Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE)

Although abemaciclib tolerability and discontinuation rates align with trial data, dose reductions are substantially more frequent in routine practice and longer follow-up is needed to establish how these reductions affect overall efficacy.

H. Abdallah, Y. Owoseni, B. Baraka et al. · 0 citations
Review Open access Aug 2026

IUC26658-92 Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations

An ethnicity-based benchmarking analysis of therapeutic outcomes across standard-of-care ICI combination regimens demonstrates consistent clinical efficacy across Asian and Caucasian populations, with no statistically significant or clinically meaningful divergence in ORR or PFS.

D. Khanna, T. Dey, E. Blanchard-Cavagis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.